{"id":"NCT02594124","sponsor":"Biogen","briefTitle":"A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies","officialTitle":"An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-04","primaryCompletion":"2023-08-21","completion":"2023-08-21","firstPosted":"2015-11-02","resultsPosted":"2024-10-22","lastUpdate":"2024-10-22"},"enrollment":292,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Spinal Muscular Atrophy"],"interventions":[{"type":"DRUG","name":"nusinersen","otherNames":["ISIS 396443","Spinraza","BIIB058","IONIS SMN Rx","ISIS SMNRx"]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"EXPERIMENTAL"},{"label":"Group 3","type":"EXPERIMENTAL"},{"label":"Group 4","type":"EXPERIMENTAL"},{"label":"Group 5","type":"EXPERIMENTAL"}],"summary":"The primary objective is to evaluate long-term safety and tolerability of nusinersen (ISIS 396443) administered by intrathecal (IT) injection to participants with Spinal Muscular Atrophy (SMA) who previously participated in investigational studies of nusinersen. The secondary objective is to examine the long-term efficacy of nusinersen administered by IT injection to participants with SMA who previously participated in investigational studies of nusinersen.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"From Day 1 up to the end of the study (up to 2848 days)","effectByArm":[{"arm":"Infantile SMA Onset CS3A","deltaMin":13,"sd":null},{"arm":"Infantile SMA Onset CS3B Previous Control","deltaMin":24,"sd":null},{"arm":"Infantile SMA Onset CS3B Previous ISIS 396443","deltaMin":65,"sd":null},{"arm":"Infantile SMA Onset 232SM202","deltaMin":12,"sd":null},{"arm":"Later SMA Onset CS12 Type 2","deltaMin":20,"sd":null},{"arm":"Later SMA Onset CS12 Type 3","deltaMin":25,"sd":null},{"arm":"Later SMA Onset CS4 Previous Control","deltaMin":42,"sd":null},{"arm":"Later SMA Onset CS4 Previous ISIS 396443","deltaMin":80,"sd":null},{"arm":"Later SMA Onset 232SM202","deltaMin":8,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":47,"countries":["United States","Australia","Belgium","Canada","France","Germany","Hong Kong","Italy","Japan","South Korea","Spain","Sweden","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://www.curesma.org","http://mda.org/disease/spinal-muscular-atrophy","https://www.rarediseases.org"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":13},"commonTop":["Pyrexia","Upper respiratory tract infection","Scoliosis","Vomiting","Procedural pain"]}}